查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607170

全球基因融合测试市场：按技术、适应症、应用和最终用户划分 - 2025-2030 年预测

Gene Fusion Testing Market by Technique (Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Nanostring), Indication (Haematological Malignacies, Solid Tumors), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年基因融合测试市值为4.2834亿美元，预计到2024年将达到4.8095亿美元，复合年增长率为12.40%，预计到2030年将达到9.7134亿美元。

基因融合测试在精准医学中极为重要，其中使用先进的定序技术来识别基因变化。基因融合测试透过检测导致肿瘤形成和遗传异常的基因重排，在癌症和其他遗传疾病的诊断和製定治疗计划中发挥着至关重要的作用。癌症盛行率的不断增加以及对透过根据个人基因谱量身定制医疗干预措施来提高治疗效果的标靶治疗的需求推动了对基因融合测试的需求。基因融合测试广泛应用于临床肿瘤学、基因研究和个人化医疗，最终用户范围从医院、诊断实验室到学术和研究机构。市场成长受到基因组研究投资增加、次世代定序技术进步以及对精准医学治疗日益接受的影响。潜在的机会包括非肿瘤领域的扩大应用、高性能筛检的技术进步以及分子诊断测试的监管要求。然而，测试成本高、测试通讯协定缺乏标准化以及复杂的报销环境等挑战阻碍了市场的扩张。由于技术障碍以及需要熟练专家解释结果，他们也面临限制。利用创新并加速研究，专注于具有成本效益且易于使用的诊断平台，整合人工智慧进行资料解释，以及与生物技术公司合作增强技术将有助于业务成长的有效途径。市场是动态的，技术进步和不断变化的监管环境共同推动市场。在资料分析和用户友好的测试解决方案方面进行创新的公司最有能力利用当前的势头。透过与医疗保健提供者持续合作的回馈和改进也将推动这一领域的发展，并可以提高治疗的临床相关性和有效性。

主要市场统计
基准年[2023] 4.2834亿美元
预计年份 [2024] 48095万美元
预测年份 [2030] 97134万美元
复合年增长率（%） 12.40%

市场动态：揭示快速发展的基因融合测试市场的关键市场洞察

供需的动态交互作用正在改变基因融合测试市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球癌症盛行率上升
    • 基因组和分子生物学研究的增加
    • 广泛用于生物标记发现
  • 市场限制因素
    • 基因融合测试高成本且机会有限
  • 市场机会
    • 液态切片基因融合检测技术的出现
    • 个人化医疗和标靶治疗的趋势
  • 市场问题
    • 严格的法规和缺乏熟练的专业人员

波特五力：驾驭基因融合测试市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基因融合检测市场的外部影响

外部宏观环境因素在塑造基因融合检测市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解基因融合检测市场的竞争状况

对基因融合测试市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵：基因融合测试市场供应商绩效评估

FPNV定位矩阵是评估基因融合测试市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製基因融合测试市场的成功之路

基因融合测试市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3. 塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的癌症发生率正在上升
      • 基因组和分子生物学研究的增加
      • 广泛用于生物标记发现
    • 抑制因素
      • 获得基因融合测试的费用昂贵且有限
    • 机会
      • 液态生物检体基因融合检测技术的出现
      • 个人化医疗和标靶治疗的趋势
    • 任务
      • 严格的法规和缺乏熟练的专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 基因融合测试市场：依技术分类

  • 介绍
  • 萤光杂合反应萤光（FISH）
  • 免疫组织化学 (IHC)
  • 奈米线
  • NGS扩增子
  • 逆转录聚合酵素链锁反应(RT-PCR)

第七章 基因融合测试市场：依适应症分类

  • 介绍
  • 骨髓恶性肿瘤
  • 固态肿瘤

第八章 基因融合测试市场：依应用分类

  • 介绍
  • 疾病诊断
  • 研究

第九章 基因融合测试市场：依最终用户分类

  • 介绍
  • 学术研究中心
  • 医院和诊断实验室
  • 製药和生物技术公司

第十章 北美、南美基因融合检测市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太基因融合检测市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东、非洲基因融合检测市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Amoy Diagnostics Co., Ltd.
  • Arima Genomics, Inc.
  • Biocare Medical, LLC
  • Biocartis NV
  • Caris Life Sciences
  • Danaher Corporation
  • Empire Genomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.
  • OncoDNA SA
  • Paragon Genomics, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated.
  • SOPHiA GENETICS SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-2E76C3E47FBF

The Gene Fusion Testing Market was valued at USD 428.34 million in 2023, expected to reach USD 480.95 million in 2024, and is projected to grow at a CAGR of 12.40%, to USD 971.34 million by 2030.

Gene fusion testing is critical in the precision medicine landscape, identifying genetic alterations through advanced sequencing techniques. It plays a pivotal role in diagnosing and developing treatment plans for cancer and other genetic disorders by detecting gene rearrangements that can drive tumorigenesis or genetic malfunctions. The necessity of gene fusion testing is driven by the increasing incidence of cancer and the demand for targeted therapies, which enhance treatment efficacy by tailoring medical interventions to individual genetic profiles. It is applied extensively in clinical oncology, genetic research, and personalized medicine, with end-users ranging from hospitals and diagnostic laboratories to academic and research institutions. Market growth is influenced by rising investments in genomic research, advancements in next-generation sequencing technologies, and the growing acceptance of precision medicine treatments. Potential opportunities include expanding applications in non-oncology segments, technological advancements in high-throughput screening, and regulatory mandates for molecular diagnostic tests. However, challenges such as high testing costs, a lack of standardization in test protocols, and complex reimbursement environments hinder market expansion. The market faces limitations posed by technological barriers and the necessity for skilled professionals to interpret results. To leverage innovation and foster research, focusing on cost-effective and easy-to-use diagnostic platforms, artificial intelligence integration for data interpretation, and partnerships with biotechnology firms for technique enhancement are viable pathways for business growth. The market is dynamic, driven by both technological advancements and evolving regulatory landscapes. Companies poised to innovate in data analytics and user-friendly testing solutions are best positioned to capitalize on the current momentum. Continuous collaboration with healthcare providers for feedback and improvements could also drive the sector towards achieving greater clinical relevance and efficacy in medical treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 428.34 million
Estimated Year [2024] USD 480.95 million
Forecast Year [2030] USD 971.34 million
CAGR (%) 12.40%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Fusion Testing Market

The Gene Fusion Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer worldwide
    • Increasing genomic and molecular biology reserach
    • Extensive use for discovery of biomarkers
  • Market Restraints
    • High cost and limited accessibility to gene fusion testing
  • Market Opportunities
    • Advent of liquid-biopsy based gene fusion testing technologies
    • Inclination towards personalize medicine and targeted therapies
  • Market Challenges
    • Stringent regulations and dearth of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Gene Fusion Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Fusion Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Fusion Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Fusion Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Fusion Testing Market

A detailed market share analysis in the Gene Fusion Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Fusion Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Fusion Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gene Fusion Testing Market

A strategic analysis of the Gene Fusion Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gene Fusion Testing Market, highlighting leading vendors and their innovative profiles. These include Amoy Diagnostics Co., Ltd., Arima Genomics, Inc., Biocare Medical, LLC, Biocartis NV, Caris Life Sciences, Danaher Corporation, Empire Genomics, Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Myriad Genetics, Inc., Natera, Inc., NeoGenomics, Inc., OncoDNA SA, Paragon Genomics, Inc., QIAGEN N.V., Quest Diagnostics Incorporated., SOPHiA GENETICS SA, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Gene Fusion Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technique, market is studied across Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Nanostring, NGS Amplicon, and Reverse Transcription Polymerase Chain Reaction (RT-PCR).
  • Based on Indication, market is studied across Haematological Malignacies and Solid Tumors.
  • Based on Application, market is studied across Disease Diagnosis and Research.
  • Based on End User, market is studied across Academic & Research Centers, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer worldwide
      • 5.1.1.2. Increasing genomic and molecular biology reserach
      • 5.1.1.3. Extensive use for discovery of biomarkers
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited accessibility to gene fusion testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Advent of liquid-biopsy based gene fusion testing technologies
      • 5.1.3.2. Inclination towards personalize medicine and targeted therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations and dearth of skilled professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gene Fusion Testing Market, by Technique

  • 6.1. Introduction
  • 6.2. Fluorescence In Situ Hybridization (FISH)
  • 6.3. Immunohistochemistry (IHC)
  • 6.4. Nanostring
  • 6.5. NGS Amplicon
  • 6.6. Reverse Transcription Polymerase Chain Reaction (RT-PCR)

7. Gene Fusion Testing Market, by Indication

  • 7.1. Introduction
  • 7.2. Haematological Malignacies
  • 7.3. Solid Tumors

8. Gene Fusion Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Disease Diagnosis
  • 8.3. Research

9. Gene Fusion Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Centers
  • 9.3. Hospitals & Diagnostic Laboratories
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Gene Fusion Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gene Fusion Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gene Fusion Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amoy Diagnostics Co., Ltd.
  • 2. Arima Genomics, Inc.
  • 3. Biocare Medical, LLC
  • 4. Biocartis NV
  • 5. Caris Life Sciences
  • 6. Danaher Corporation
  • 7. Empire Genomics, Inc.
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Guardant Health, Inc.
  • 10. Illumina, Inc.
  • 11. Integrated DNA Technologies, Inc.
  • 12. Myriad Genetics, Inc.
  • 13. Natera, Inc.
  • 14. NeoGenomics, Inc.
  • 15. OncoDNA SA
  • 16. Paragon Genomics, Inc.
  • 17. QIAGEN N.V.
  • 18. Quest Diagnostics Incorporated.
  • 19. SOPHiA GENETICS SA
  • 20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GENE FUSION TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. GENE FUSION TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENE FUSION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENE FUSION TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NANOSTRING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NGS AMPLICON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HAEMATOLOGICAL MALIGNACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2023